Table 2.
List of commercialized BPs for bone disorders
| Brand name | Active ingredient | Application | FDA approval year | Company |
|---|---|---|---|---|
| Didronel | Etidronate | Paget’s disease, Irregular Bone Growth | 1987 | MGI Pharma |
| Aredia | Pamidronate | Hypercalcemia of Malignancy, Paget’s disease, Bone damage caused by breast/bone marrow cancer | 1991 | Pfizer |
| Fosamax | Alendronate | Osteoporosis | 1995 | Merck |
| Skelid | Tiludronate | Paget’s disease | 1997 | Sanofi |
| Actonel | Risedronate | Osteoporosis, Paget’s disease | 1998 | Procter & Gamble Pharmaceuticals |
| Zometa | Zoledronate | Hypercalcemia of Malignancy, Multiple Myeloma | 2002 | Novartis |
| Boniva | Ibandronate | Osteoporosis | 2003 | Roche Therapeutics |
| Fosamax Plus D | Alendronate / Cholecalciferol | Osteoporosis | 2005 | Merck |
| Actonel with Calcium | Risedronate / Calcium Carbonate | Osteoporosis, Paget’s disease | 2005 | Procter & Gamble Pharmaceuticals |
| Aclasta | Zoledronate | Osteoporosis, Paget’s disease | 2007 | Novartis |
| Reclast | Zoledronate | Osteoporosis | 2007 | Novartis |
| Atelvia | Risedronate | Osteoporosis | 2010 | Sanofi |
| Binosto | Alendronate | Osteoporosis | 2012 | EffRx Pharmaceuticals SA |